| Drug Name: | Glucagon (64790-15-4) |
|---|---|
| PubChem ID: | 3080901 |
| SMILES: | CC(C)CC(C(=O)NC(CCSC)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(C)N |
| InchiKey: | SVHJFTNFNMWDBS-FPLSMPAJSA-N |
| Therapeutic Category: |
| Molecular Weight (dalton) | : | 1352.53 |
| LogP | : | -4.05 |
| Ring Count | : | 3 |
| Hydrogen Bond Acceptor Count | : | 18 |
| Hydrogen Bond Donor Count | : | 18 |
| Total Polar Surface Area | : | 556.91 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Cell Death | cAMP-dependent protein kinase (P17612) | Direct pharmacological evidence for the activation of the cAMP-dependent protein kinase in response to glucagon in the intact cell@which leads to cell death. [ ADR Type 2 ] | A study of the mechanism of glucagon-induced protein phosphorylation in isolated rat hepatocytes using (Sp)-cAMPS and (Rp)-cAMPS, the stimulatory and inhibitory diastereomers of adenosine cyclic 3',5'-phosphor |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category